mash glp 1 Incretin-based therapies in MASLD/MASH: from GLP-1 receptor agonists to dual and triple agonists - Incretin-based therapies in MASLD/MASH: from

Discover trends in diabetes care, weight-loss demand, pricing, and generics.

Discover how weight loss medications affect pregnancy and fertility with the latest insights, research, and safety recommendations for patients.

Discover female-specific factors, common causes, and evidence-based strategies to optimize your tirzepatide therapy for effective weight management.

June 2, 2026 Results of an American College of Radiology-managed retrospective study involving 110,000 womenpresented at the 2026 ASCO Annual Meeting, shows that those who took GLP-1 medications were up to 35% less likely to develop breast cancer than those who did not take GLP-1 drugs. ACR urges funding of a large prospective study to clarify impact of these drugs on cancer incidence and prevention.

Something unprecedented will happen during advertisings biggest night